Exozymes Inc.

EXOZ Nasdaq SEC CIK 2010788
Follow Exozymes Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$2.2M +2.1% vs same quarter last year
EPS, diluted −$0.24 +11.1% vs same quarter last year
Operating cash flow −$2.2M −19.7% vs same quarter last year
Operating income −$3M −20.8% vs same quarter last year
Net income by quarter
−$1.8M
−$1.9M
−$2.4M
−$2.3M
−$2.7M
−$2.4M
−$2.9M
−$2.2M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income4 fiscal years
−$10M−$7.5M−$5M−$2.5M$0FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$9.2M
FY24−$5.9M
FY23−$2M
FY22-
Free cash flowOperating cash flow minus capital expenditure
−$10M−$7.5M−$5M−$2.5M$0FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$6.7M
FY24−$8.9M
FY23−$1.5M
FY22-